We characterized the hepatic and intestinal UDP-glucuronosyltransferase (UGT) isoform(s) responsible for the glucuronidation of 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetic acid (TA-1801A) in humans through several in vitro mechanistic studies. Assessment of a panel of recombinant UGT isoforms revealed the TA-1801A glucuronosyltransferase activity of UGT1A1, UGT1A3, UGT1A7, UGT1A9, and UGT2B7. Kinetic analyses of the TA-1801A glucuronidation by recombinant UGT1A1, UGT1A3, UGT1A9, and UGT2B7 showed that the Km value for UGT2B7 was apparently consistent with those in human liver and jejunum microsomes. The TA-1801A glucuronosyltransferase activity in human liver microsomes was inhibited by bilirubin (typical substrate for UGT1A1), propofol (typical substrate for UGT1A9), diclofenac (substrate for UGT1A9 and UGT2B7), and genistein (substrate for UGT1A1, UGT1A3, and UGT1A9). The inhibition by bilirubin, propofol, and diclofenac of the TA-1801A glucuronidation was less pronounced in jejunum microsomes than liver microsomes, suggesting that the contribution of UGT1A1, UGT1A9, and UGT2B7 to the TA-1801A glucuronidation is smaller in the intestine than the liver. In contrast, genistein strongly inhibited the TA-1801A glucuronosyltransferase activity in both human liver and jejunum microsomes. These results suggest that the glucuronidation of TA-1801A is mainly catalyzed by UGT1A1, UGT1A9, and UGT2B7 in the liver, and by UGT1A1, UGT1A3, and UGT2B7 in the intestine in humans.
Introduction
When TA-1801, 1) an ester prodrug of TA-1801A [2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetic acid, Fig. 1 ], was administered orally to humans, the glucuronide of TA-1801A was the most abundant metabolite in human urine.
2) There were signiˆcant species and tissue diŠerences in the TA-1801A glucuronosyltransferase activities. It was demonstrated that the activity of the TA-1801A glucuronidation in human intestinal microsomes is as well as that in human liver microsomes. 2) To date, 18 functional UDP-glucuronosyltransferase (UGT) isoforms have been identiˆed in humans and classiˆed on the basis of primary amino acid sequence into two families of protein termed UGT1 and UGT2. 3) UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, and UGT2B17 are expressed in human liver. [4] [5] [6] UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A10, UGT2B4, UGT2B7, UGT2B10, and UGT2B15 are expressed in human intestine. [4] [5] [6] Several genetic polymorphisms have been identiˆed in the UGT family. 4, 7, 8) The determination of the identity of the enzymes involved in drug metabolism is important to understand the variation in drug eŠect and metabolism. Moreover, the identiˆcation of the drug-metabolizing enzymes (e.g. cytochrome P450 and UGT) could provide essential information about potential drug-drug interaction, since many enzymes are involved in the metabolism of several xenobiotics. 9, 10) A number of approaches have been developed for the identiˆcation of human UGTs on the glucuronidation of endogenous and exogenous compounds in vitro. 4, [11] [12] [13] In the present study, to identify the human UGT isoform(s) responsible for the TA-1801A glucuronidation, the activities and kinetics of recombinant human UGT microsomes were determined. Furthermore, we performed the inhibition analyses using typical substrates for UGT isoforms to conˆrm the contribution of enzymes to the TA-1801A glucuronidation in human liver and jejunum microsomes.
Materials and Methods
Materials: TA-1801A was synthesized at Tanabe Seiyaku Co., LTD. (Saitama, Japan). UDP-glucuronic acid, alamethicin, propofol, and genistein were purchased from Sigma-Aldrich (St. Louis, MO). Bilirubin was obtained from Wako Pure Chemicals (Osaka, Japan), and diclofenac was from Ultraˆne Chemicals and Research (Manchester, UK). Pooled human liver microsomes from donors (13 males, 4-62 years old; 9 females, 40-74 years old) were purchased from BD Gentest (Woburn, MA). Recombinant human UGTs (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7,  UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7,  UGT2B15 , and UGT2B17) expressed in baculovirusinfected insect cells (Supersomes) were also from BD Gentest. Pooled human jejunum microsomes from donors (ˆve males, 19-55 years old;ˆve females, 16-51 years old) were obtained from Tissue Transformation Technologies (Edison, NJ). The protein contents were used as described in the data sheets provided by the manufacturer. All other chemicals and solvents were of the highest grade commercially available.
TA-1801A glucuronidation assay: TA-1801A glucuronosyltransferase activities in human liver and jejunum microsomes, and recombinant UGTs were determined as described previously.
2) Brie‰y, a typical incubation mixture (100-mL total volume) contained 50 mM Tris-HCl buŠer, pH 7.5, 8 mM MgCl2, 2 mM UDP-glucuronic acid, 25 mg W mL alamethicin, 0.2 mg W mL human liver microsomes (human jejunum microsomes or recombinant UGTs), and 12.5, 20, or 100 mM TA-1801A. The glucuronosyltransferase activities of 12 recombinant UGTs were determined in assays using HPLC, and 7-hydroxy 4-tri‰uoromethylcoumarin or tri‰uoperazine as substrates previously. 13) We conˆrmed that all recombinant UGTs were enough active to determine the TA-1801A glucuronidation. Kinetic analyses: The kinetics studies were performed using recombinant UGTs (UGT1A1, UGT1A3, UGT1A9, and UGT2B7) expressed in microsomes. In determining the kinetic parameters, the TA-1801A concentration ranged from 1.56 to 400 mM. Kinetic parameters were estimated from theˆtted curves using the Prism computer program (GraphPad Software Inc., San Diego, CA), designed for nonlinear regression analysis. The following equations were applied for Michaelis-Menten kinetics (eq. 1), substrate inhibition kinetics (eq. 2), or Hill equation (eq. 3) previously 12) :
where V is the rate of reaction, Vmax is the maximum velocity, Km is Michaelis constant (substrate concentration at 0.5V max ), [ S ] is the substrate concentration, K si is the constant describing the substrate inhibition interaction, S50 is the substrate concentration resulting in 50z of Vmax (analogous to Km), and n is the Hill coe‹cient. Inhibition analysis of TA-1801A glucuronosyltransferase activities in human liver and jejunum microsomes: Four compounds were tested for their inhibitory eŠects on the TA-1801A glucuronosyltransferase activity. Bilirubin is a typical substrate for UGT1A1. 14, 15) Propofol is a typical substrate for UGT1A9. 16, 17) Diclofenac is a substrate for UGT1A9 and UGT2B7. 18, 19) Genistein is a substrate for UGT1A1, UGT1A3, and UGT1A9. 5, 20) Bilirubin, propofol, diclofenac, and genistein were dissolved in dimethyl sulfoxide, with the solvent being used as the control. Theˆnal concentration of organic solvents (the mixture of methanol and dimethyl sulfoxide) in the reaction mixture was 2z (v W v). Organic solvents tested up to 2z (v W v) had no eŠect on the formation of TA-1801A glucuronide. The inhibitor concentrations for IC25 and IC 50 determinations in human liver or jejunum microsomes were 1 to 300 mM. Each incubation contained 0.2 mg W mL microsomal protein. The glucuronosyltransferase activities in human liver and jejunum microsomes at 20 mM TA-1801A were determined as described above. The IC 25 and IC 50 values were estimated graphically.
Selectivity of UGT inhibitors towards recombinant UGTs: For the determination of the inhibitory eŠects of various UGT substrates on recombinant UGT1A1, UGT1A3, UGT1A9, and UGT2B7, the inhibitor concentrations were chosen at or near IC25 and IC50 in human liver microsomes. Each incubation contained 0.3 mg W mL microsomal protein. The glucuronosyltransferase activities of recombinant UGTs (UGT1A1, Fig. 2 . TA-1801A glucuronosyltransferase activity of recombinant human UGTs. TA-1801A glucuronosyltransferase activities of recombinant UGTs were determined at 12.5 or 100 mM TA-1801A. Each column represents the mean±S.D. of triplicate determinations. The lower limit of quantitation of the assay under these conditions was 10 pmol W min W mg protein.
UGT1A3, UGT1A9, and UGT2B7) expressed in microsomes at 20 mM TA-1801A were determined as described above.
Results
TA-1801A glucuronidation in recombinant UGT isoforms: All recombinant UGT isoforms expressed in baculovirus-infected insect cells were used to determine their TA-1801A glucuronosyltransferase activities (Fig. 2) . At high substrate concentration (100 mM), UGT1A1, UGT1A9, and UGT2B7 exhibited high TA-1801A glucuronosyltransferase activities, in addition, UGT1A3 and UGT1A7 exhibited TA-1801A glucuronosyltransferase activities. At middle substrate concentration (12.5 mM), UGT1A1, UGT1A9, and UGT2B7 exhibited the TA-1801A glucuronosyltransferase activities. All other isoforms (UGT1A4, UGT1A6, UGT1A8, UGT1A10, UGT2B4, UGT2B15, and UGT2B17) had very low TA-1801A glucuronosyltransferase activities (º10 pmol W min W mg protein) or no activities.
Kinetics of TA-1801A glucuronidation in recombinant UGTs: Kinetics analyses of the TA-1801A glucuronidation in recombinant UGT1A1, UGT1A3, UGT1A9, and UGT2B7 were performed. As shown in Fig. 3 , A and D, the TA-1801A glucuronidation by UGT1A1 and UGT2B7 displayed typical MichaelisMenten kinetics. In contrast, UGT1A3-catalyzed glucuronidation followed a sigmoidal kinetic (Fig. 3B) , which manifests as a curvilinear Eadie-Hofstee plot. In addition, glucuronidation by UGT1A9 showed a complex kinetic with decreasing velocity at higher substrate concentration (Fig. 3C) , suggesting the eŠect of substrate inhibition. Fitting the data points to the eq. 1, 2, or 3 yielded the kinetic parameters listed in Table 1 . The K m values for recombinant UGT1A1 and UGT2B7 were 138±5.9 and 45.6±2.8 mM, respectively. Additionally, the S50 value for recombinant UGT1A3 was 293±67 mM. With respect to recombinant UGT1A9, the Km value was 11.9±0.7 mM.
Inhibition analyses of TA-1801A glucuronidation in human liver and jejunum microsomes: The inhibitory eŠects of bilirubin (UGT1A1), propofol (UGT1A9), diclofenac (UGT1A9 and UGT2B7), and genistein (UGT1A1, UGT1A3, and UGT1A9) on the TA-1801A glucuronosyltransferase activities in human liver and jejunum microsomes were determined. As shown in Fig. 4A , the TA-1801A glucuronosyltransferase activity in human liver microsomes was prominently inhibited by diclofenac and genistein (IC25 and IC50 are 10 and 36 mM for diclofenac, 4 and 15 mM for genistein, respectively). The inhibitory eŠect of propofol (IC25 and IC50 are 31 and 111 mM, respectively) was also conˆrmed, and bilirubin partly inhibited the activity by approximately 40z (IC25 and IC50 are 2 and À300 mM, respectively). In contrast, the TA-1801A glucuronosyltransferase activity in human jejunum microsomes was prominently inhibited by genistein (IC25 and IC50 are 10 and 20 mM, respectively) as shown in Fig. 4B . The inhibitory eŠects of diclofenac (IC25 and IC50 are 21 and 138 mM, respectively), propofol (IC 25 and IC 50 are 86 and 285 mM, respectively), and bilirubin (IC25 and IC50 are 40 and À300 mM, respectively) were moderately.
Selectivity of UGT inhibitors towards recombinant UGTs: To determine the UGT isoform selectivity of inhibition by compounds, we investigated the inhibitory eŠects on the TA-1801A glucuronidation by recombinant human UGT isoforms (Fig. 5) . Bilirubin strongly inhibited the TA-1801A glucuronosyltransferase activity of UGT1A1 by 64.7z at 3 mM, and 95.7z at 100
Fig. 3. Kinetics of TA-1801A glucuronidation by recombinant UGT1A1 (A), UGT1A3 (B), UGT1A9 (C), and UGT2B7 (D).
The concentration of TA-1801A ranged from 1.56 to 400 mM. TA-1801A glucuronosyltransferase activities were determined as described under Materials and Methods. Each inset shows the Eadie-Hofstee plot of the experimental data. Each incubation was performed by triplicate determinations. mM, respectively, whereas the inhibitory eŠect was very weak for UGT1A3, UGT1A9, and UGT2B7. Propofol eŠectively inhibited the TA-1801A glucuronosyltransferase activity of UGT1A9 by 33.5z at 30 mM, and 65.4z at 100 mM, respectively. The inhibitory eŠect at 30 mM was weak for UGT1A1 and UGT2B7, but at 100 mM was moderate for them, whereas was very weak for UGT1A3. Diclofenac eŠectively inhibited the TA-1801A glucuronosyltransferase activity of UGT2B7 by 40.6z at 10 mM, and 67.0z at 30 mM, respectively. The inhibitory eŠect was relatively weak for UGT1A1 and UGT1A9, whereas was very weak for UGT1A3. On the other hand, genistein inhibited the TA-1801A glucuronosyltransferase activities of UGT1A1 (by 38.8z at 3 mM, and 97.6z at 30 mM, respectively), UGT1A3 (by 11.4z at 3 mM, and 47.4z at 30 mM, respectively), and UGT1A9 (by 25.4z at 3 mM, and 79.5z at 30 mM, respectively). The inhibitory eŠect was relatively weak for UGT2B7.
Discussion
In the present study, the metabolism of TA-1801A to its glucuronide was investigated with several insect cell microsomes expressing human UGTs as well as human liver and jejunum microsomes. Consequently, recombinant UGT1A1, UGT1A9, and UGT2B7 showed signiˆcant glucuronosyltransferase activities both at middle and high substrate concentrations among the UGT isoforms examined (Fig. 2) . Recombinant UGT1A3 and Fig. 4 . Inhibitory eŠects of typical substrates for UGT isoforms on TA-1801A glucuronosyltransferase activity in human liver (A) or jejunum (B) microsomes. TA-1801A glucuronosyltransferase activities at 20 mM TA-1801A in pooled human liver and jejunum microsomes were determined as described under Materials and Methods. Bilirubin (UGT1A1), propofol (UGT1A9), diclofenac (UGT1A9 and UGT2B7), and genistein (UGT1A1, UGT1A3, and UGT1A9) were used as inhibitors. Control activities in the pooled human liver and jejunum microsomes in the absence of inhibitor were 348±10.4 and 660±18.0 pmol W min W mg protein, respectively. Each value represents the mean±S.D. of triplicate determinations. UGT1A7 also catalyzed the TA-1801A glucuronidation, although it has been reported that UGT1A7 is expressed in human esophagus and stomach, but not in human liver and intestine. 4, 21) Theseˆndings suggest that multiple UGT isoforms are involved in the glucuronidation of TA-1801A in human liver and intestine. Furthermore, to clarify the contribution among UGT enzymes to the TA-1801A glucuronidation we performed kinetic analyses of recombinant human UGT microsomes, as was the case with human liver and jejunum microsomes.
In the previous study, the kinetic pattern of the TA-1801A glucuronidation was monophasic in human liver and jejunum microsomes.
2) The Km value for recombinant UGT2B7 of the TA-1801A glucuronidation was apparently consistent with those in human liver and jejunum microsomes (Table 1) . However, these results would not contradict the involvement of other UGTs (such as UGT1A1 and UGT1A9) on the TA-1801A glucuronidation in human liver and intestine, because the Km values for UGT1A1 and UGT1A9 are less diŠerent (within 4-fold) from that for UGT2B7.
Next, to conˆrm the involvement of multiple UGT isoforms on the TA-1801A glucuronidation in human liver and intestine, we performed the inhibition analyses using typical substrates for UGT isoforms. Bilirubin is well known to be a speciˆc substrate for UGT1A1. 14, 15) Under this condition in the present study, bilirubin selectively inhibited the TA-1801A glucuronosyltransferase activity of recombinant UGT1A1, but not UGT1A3, UGT1A9, and UGT2B7 (Fig. 5) . At a concentration of 100 mM, bilirubin almost completely inhibited the TA-1801A glucuronosyltransferase activity of recombinant UGT1A1, whereas those in human liver and jejunum microsomes were inhibited by approximately 40z (Fig. 4) . These results suggest that the contribution of UGT1A1 to the TA-1801A glucuronidation in human liver and intestine is no less than 40z of all. Propofol is known to be a typical substrate for UGT1A9. 16, 17) Additionally, diclofenac is known to be a substrate for UGT1A9 and UGT2B7. 18, 19) In our experiments, propofol inhibited the TA-1801A glucuronosyltransferase activity of not only UGT1A9 but also UGT1A1 and UGT2B7. Diclofenac inhibited the TA-1801A glucuronosyltransferase activity of UGT2B7, whereas the inhibitory eŠect was relatively weak for UGT1A1, UGT1A3, and UGT1A9 (Fig. 5) . Diclofenac and, to a lesser extent, propofol inhibited the TA-1801A glucuronosyltransferase activity in human liver microsomes. In addition, genistein, known to be a substrate for UGT1A1, UGT1A3, and UGT1A9, 5, 20) strongly inhibited the TA-1801A glucuronosyltransferase activity in human liver microsomes (Fig. 4A) . Since it has been reported that hepatic UGT1A3 mRNA levels were approximately 20-fold less than the levels of UGT1A1, 21) it is unlikely that UGT1A3 would play a role in the glucuronidation of TA-1801A in human liver. The inhibitory eŠects observed with these inhibitors in human liver microsomes suggest that the glucuronidation of TA-1801A is mainly catalyzed by UGT1A1, UGT1A9, and UGT2B7 in human liver.
Data in Fig. 4 indicate that the inhibition by bilirubin, propofol, and diclofenac of the TA-1801A glucuronidation was less pronounced in jejunum microsomes than liver microsomes, suggesting that the contribution of UGT1A1, UGT1A9, and UGT2B7 to the TA-1801A glucuronidation is smaller in the intestine than the liver. In contrast, genistein strongly inhibited the TA-1801A glucuronosyltransferase activity in both human liver and jejunum microsomes. It is considered that this phenomenon would be due to the contribution of UGT1A3 to the TA-1801A glucuronidation. It has been reported that UGT1A9 is expressed in human liver, but not in human intestine, 4, 22) whereas Albert et al. 23) reported that UGT1A9 was also expressed in human intestine. From these reports and the inhibition eŠects of propofol in the present study, it might be mentioned that the contribution of UGT1A9 to the TA-1801A glucuronidation was small in human jejunum microsomal samples used. Therefore, taking into account the inhibition observed with these inhibitors in human jejunum microsomes, it is suggested that the glucuronidation of TA-1801A is mainly catalyzed by UGT1A1, UGT1A3, and UGT2B7 in human intestine. It has been reported that the majority of carboxylic acid compounds are glucuronidated principally by UGT1A3, UGT1A9, and UGT2B7. 4, 11, 24) Bilirubin, which is also metabolized to an acyl glucuronide, is selectively glucuronidated by UGT1A1. However, bilirubin glucuronidation by UGT1A1 is a rare example of the ability of this enzyme to form carboxylic ester glucuronides, because other carboxylic acids are not glucuronidated by this protein. 15, 24) The present results were similar to these reports. But, it is interesting that UGT1A1 catalyzes the metabolism of the carboxylic acid such as TA-1801A.
In conclusion, we characterized the hepatic and intestinal UGT isoforms responsible for the glucuronidation of TA-1801A in humans through the activities and kinetics of recombinant human UGTs, and the inhibition analyses using typical substrates for UGT isoforms. These results suggest that the glucuronidation of TA-1801A is mainly catalyzed by UGT1A1, UGT1A9, and UGT2B7 in the liver, and by UGT1A1, UGT1A3, and UGT2B7 in the intestine in humans.
